

**Additional information under Art. 12, par. 1, item 4  
of the Ordinance 2 of 09.11.2021 of  
TCHAIKAPHARMA HIGH QUALITY MEDICINES INC.  
as of the 31th of March  
2024**

**1. Information on the changes in accounting policy during the reporting period, the reasons for them and how they affect the financial results and equity of the issuer.**

The consolidated financial statements of Tchaikapharma High Quality Medicines Inc. have been prepared in accordance with International Financial Reporting Standards as adopted by the European Union.

More detailed information on the company's accounting policies can be found at on item II.1. Basis of preparation of the consolidated financial statements in the Annexes to the consolidated MFR for the period 01.01.2024 - 31.03.2024.

**2. Information about changes in the economic group of the issuer as at 31 March 2024:**  
On 15.02.2024. The Company contributed BGN 50 thousand for the share capital of a second subsidiary PERPETEL EAD with the subject of activity. The company was entered in the Commercial Register on 21.02.2024 with UIC 207721193. Thus, the group of Tchaikapharma High Quality Medicines Inc. is formed by three companies.

**3. Information on the results from organizational changes made within the issuer, such as restructuring, sale of companies from the economic group, in-kind contributions from companies, rental property, long-term investments, and suspension of operation:** no changes

**4. The opinion of the Governing Body on the realization of the published forecasts for the current financial year, taking into account the results of the current quarter, and the information on the factors and circumstances that will affect the achievement of the forecast results at least for the next quarter** – no update of the projected results.

**5. For the public companies - data on persons holding directly and indirectly at least 5 percent of votes at the general meeting at the end of the quarter and changes in the votes held by persons since the end of the previous quarter:**

SHAREHOLDERS	Shares	/%/	Shares	/%/
	31.03.2024		31.12.2023	
<b>Tihomir Kamenov</b>	74 441 821	/88,10%/	74 450 360	/88,11%/
<b>PLURIBUS S. A. R. L.</b>	5 800 000	/6,86%/	5 800 000	/6,86%/

**6. Information on pending legal, administrative or arbitration procedures relating to liabilities or receivables amounting to at least 10 percent of the company's equity** – no such procedures.

**7. Information on the loans granted by the issuer or its subsidiary, by their subsidiaries, the collateral provided or the liabilities assumed in total to one person or its subsidiary, including related parties, indicating the names or titles and UIC of the person, the nature of the relationship between the issuer or its subsidiaries and the borrower, the amount of outstanding principal, interest rate, date of conclusion of the contract, including additional agreements, repayment period, amount of commitment, specific conditions other than those specified in this provision , as well as the purpose for which they are**

***granted, in case they are concluded as targets: -***

Tchaikapharma High Quality Medicines Inc. has entered into two contracts with UNITED BULGARIAN BANK, maturing on 20.12.2024. Liabilities under these contracts as of 31.03.2024 are in total amount of BGN 9,789 thousand. The interest rates applied range from 2% to 2.2%. Property, plant and equipment are pledged.


Tchaikapharma High Quality Medicines Inc. is a co-borrower on a loan to Commercial League - Global Pharmacy Center Inc. from UNITED BULGARIAN BANK under agreements dated 12.04.2019 and 03.12.2019, maturing on 30.07.2024 and 30.09.2028.

The Company is a co-borrower under a loan to Commercial League - Global Pharmacy Center AD from EUROBANK BULGARIA AD under an agreement dated 08.08.2022.

The mortgages include land properties with material interest of BGN 3,575 thousand.

Pledges include machinery and equipment with material interest of BGN 4,609 thousand.

Leases payable include three contracts for buildings and machinery, with terms from 2024 to 2026. The interest rates applied range from 2% to 2.2%.



---

Biser Georgiev  
Executive Director